By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.

Contact Information

Website: www.exelixis.com
Email: shubbard@exelixis.com
Main Phone: +1 650 837-7000
Address: 1851 Harbor Bay Parkway
State: CA
City / Town: Alameda
Country: US
Postal Code: 94502

Issuer Information

Exchange: NGS
CEO: Michael M. Morrissey
Employees: 773
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

View More
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A